Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.97 |
| ▸ | TYMP | P19971 | 1/20 | 0.55 |
| ▸ | CASP6 | P55212 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 6/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | ATM | Q13315 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28045491 | 0.98 | MAPT (1.00) | MAPTTYMPCASP6ALDH1A1LMNA | |
| Dihydroartemidin SCHEMBL28045625 | 0.95 | MAPT (0.88) | MAPTTYMPCASP6ALDH1A1LMNA | |
| SCHEMBL292962 | 0.84 | MAPT (0.71) | MAPTTYMPCASP6ALDH1A1LMNA | |
| SCHEMBL510088 | 0.83 | MAPT (0.74) | MAPTTYMPCASP6ALDH1A1LMNA | |
| SCHEMBL293278 | 0.83 | MAPT (0.68) | MAPTTYMPCASP6ALDH1A1LMNA | |
| SCHEMBL10725654 | 0.82 | MAPT (0.67) | MAPTTYMPCASP6ALDH1A1LMNA | |
| SCHEMBL28045624 | 0.81 | MAPT (0.67) | MAPTTYMPCASP6ALDH1A1LMNA | |
| SCHEMBL511169 | 0.79 | MAPT (0.63) | MAPTTYMPCASP6ALDH1A1L3MBTL1 | |
| SCHEMBL11663319 | 0.78 | MAPT (0.62) | MAPTALDH1A1LMNASMN1; SMN2TDP1 | |
| SCHEMBL6605667 | 0.78 | MAPT (0.61) | MAPTTYMPCASP6L3MBTL1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1854792-B1 | 1-(2H)-ISOQUINOLONE DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2012-12-26 | — | — | EP | disclosed |
| EP-1724262-B1 | 1-(2H)-ISOQUINOLONE DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2012-05-02 | — | — | EP | disclosed |
| US-8143274-B2 | 1-(2H)-isoquinolone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-03-27 | — | — | US | disclosed |
| US-7820693-B2 | 1-(2H)-isoquinolone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-10-26 | — | — | US | disclosed |
| US-20090030195-A1 | 1-(2H)-ISOQUINOLONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-01-29 | — | — | US | disclosed |
| EP-1854792-A1 | 1-(2H)-ISOQUINOLONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-11-14 | — | — | EP | disclosed |
| US-20070185160-A1 | 1-(2H)-isoquinolone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-08-09 | — | — | US | disclosed |
| CN-1301951-C | Method for producing deoxybenzoins | BASF AG (DE) | 2007-02-28 | — | — | CN | disclosed |
| EP-1724262-A1 | 1-(2H)-ISOQUINOLONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2006-11-22 | — | — | EP | disclosed |
| CN-1602289-A | Method for producing deoxybenzoin | BASF AG (DE) | 2005-03-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185160-A1 | 1-(2H)-isoquinolone derivative | NR3C2, NR1H4, NR3C1 | MAPT 3539/4885TYMP 4873/4885CASP6 3871/4885 |
| US-20090030195-A1 | 1-(2H)-ISOQUINOLONE DERIVATIVE | NQO1, NR5A1, SRD5A1 | MAPT 4671/4885TYMP 535/4885CASP6 2596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.